Trials / Recruiting
RecruitingNCT06560294
Glue Embolization vs Conservative Treatment for Pelvic Congestion Syndrome
Glue Embolization Versus Conservative Treatment for Pelvic Congestion Syndrome: A Randomized Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- Female
- Age
- 30 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to compare glue embolization and conservative treatment for pelvic congestion syndrome regarding safety and efficacy.
Detailed description
Pelvic congestion syndrome (PCS) is a common cause of chronic lower abdominal/pelvic pain, estimated to affect about 40 % of women, predominantly between the ages of 30 and 45.The treatment of PCS depends mainly on the severity of the pain. Non-steroid anti-inflammatory drugs are often used, and contraceptives have a role in cases of pain associated predominantly with menstruation. Traditionally, conservative approaches, such as pharmacotherapy with venoactive drugs like micronized purified flavonoid fraction (Daflon), have been utilized to address the symptoms of PCS. Daflon has been used to treat venous insufficiency and has demonstrated efficacy in reducing symptoms and improving the quality of life in patients with PCS. Its mechanism of action includes improving venous tone, reducing venous stasis, and exerting anti-inflammatory effects. Endovascular treatment of PCS is challenging and requires occlusion of incompetent pelvic veins.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Micronized purified flavonoid fraction (Daflon ®) | Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months. |
| OTHER | Glue embolization | Patients will receive transcatheter glue embolization. |
Timeline
- Start date
- 2024-08-17
- Primary completion
- 2025-10-01
- Completion
- 2025-10-01
- First posted
- 2024-08-19
- Last updated
- 2025-08-19
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06560294. Inclusion in this directory is not an endorsement.